

State of Oklahoma SoonerCare Lumoxiti[®] (Moxetumomab Pasudotox-tdfk) Prior Authorization Form

Pri		rior Authorization Form	
Member Name:	Date of Birth:	Member ID#:	
	Drug Information	n	
Physician billing (HCPCS o	code:) Start Date (or	e:) Start Date (or date of next dose):	
Dose:	Regimen:		
	Billing Provider Inform	mation	
Provider NPI:	Provider Name:		
Provider Phone:	Provider Fa	ax:	
	Prescriber Informa	tion	
Prescriber NPI:	Prescriber Name:		
Prescriber Phone:	Prescriber Fax:	Specialty:	
	Criteria		
 B. Has the membrance nucleoside ana C. Please provide D. Will moxetumo If answer is none 	nia (HCL) ed or refractory? Yes No er received at least 2 prior systemic t alog (PNA)? Yes No e member's creatinine clearance: mab pasudotox-tdfk be used as a sin	nosis:	

For Continued Authorization:

- 1. Date of last dose:
- 2. Does member have any evidence of progressive disease while on moxetumomab pasudotox-tdfk? Yes____ No____
- 3. Has the member experienced adverse drug reactions related to moxetumomab pasudotox-tdfk therapy? Yes____ No____

If yes, please specify adverse reactions:_____

Prescriber Signature:

Date:

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:	CONFIDENTIALITY NOTICE
University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit	This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error,
Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4	please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.